Aktis Oncology, Inc.

NasdaqGS:AKTS Stock Report

Market Cap: US$1.4b

Aktis Oncology Management

Management criteria checks 4/4

Aktis Oncology's CEO is Matthew Roden, appointed in Sep 2020, has a tenure of 5.83 years. total yearly compensation is $914.68K, comprised of 63.3% salary and 36.7% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $2.29M. The average tenure of the management team and the board of directors is 3.2 years and 3.1 years respectively.

Key information

Matthew Roden

Chief executive officer

US$914.7k

Total compensation

CEO salary percentage63.33%
CEO tenure5.8yrs
CEO ownership0.2%
Management average tenure3.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 28

Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting

Summary Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b Part 1 data in Q1 2027 and AKY-2519 ASCO poster presentations and phase 1b initiation in mid-2026. The company’s approach aims to expand the radiopharmaceutical market beyond PSMA and SSTR2, leveraging alpha-emitting actinium-225 for broader tumor targeting potential. With $562.1 million pro forma cash post-IPO, the company is funded into 2029, supporting multiple pipeline milestones and reducing near-term dilution risk. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Matthew Roden's remuneration changed compared to Aktis Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$67m

Dec 31 2025US$915kUS$579k

-US$64m

Sep 30 2025n/an/a

-US$61m

Dec 31 2024US$5mUS$455k

-US$44m

Compensation vs Market: Matthew's total compensation ($USD914.68K) is below average for companies of similar size in the US market ($USD5.16M).

Compensation vs Earnings: Matthew's compensation has been consistent with company performance over the past year.

CEO

Matthew Roden

5.8yrs
Tenure
US$914,680
Compensation

Dr. Matthew Roden, also known as Matt, Ph.D. is Executive Partner & Entrepreneur of MPM Asset Management, L.L.C. from September 17, 2020. Dr. Roden is President, CEO and Director of Aktis Oncology, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
Todd Foley
Co-Founder & Chairman5.9yrsno data0%
$ 0
Matthew Roden
President5.8yrsUS$914.68k0.17%
$ 2.3m
Paul Feldman
Chief Scientific Officer5.6yrsUS$642.42k0.26%
$ 3.6m
Akos Czibere
Chief Medical Officer2yrsUS$902.68k0%
$ 0
Patrick Baeuerle
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Kyle Kuvalanka
Chief Financial Officerless than a yearno datano data
Shulamit Ron-Bigger
Chief Operating Officer3.8yrsUS$1.41m0%
$ 0
Tyler Benedum
Chief Technical Officer2.2yrsno datano data
Carlos Rodriguez
Executive Director of Corporate Developmentno datano datano data
Dasa Lipovsek
VP & Head of Lead Discovery4.5yrsno datano data
Lorraine Horgan
VP & Head of Program Managementno datano datano data
Jeff Kovacs
VP & Head of Biology2.5yrsno datano data
3.2yrs
Average Tenure
54yo
Average Age

Experienced Management: AKTS's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Todd Foley
Co-Founder & Chairman5.9yrsno data0%
$ 0
Matthew Roden
President5.8yrsUS$914.68k0.17%
$ 2.3m
Patrick Baeuerle
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Lloyd Segal
Independent Director5.4yrsUS$45.00k0.036%
$ 488.6k
Mary Thistle
Independent Director1.5yrsUS$45.00k0%
$ 0
Karl Wittrup
Member of Scientific Advisory Boardno datano datano data
Pankaj Bhargava
Member of Scientific Advisory Board2yrsno datano data
Johannes Czernin
Member of Scientific Advisory Boardno datano datano data
Erik Chelius
Member of Scientific Advisory Boardno datano datano data
Germo Gericke
Member of Scientific Advisory Board3.1yrsno datano data
Ken Herrmann
Chair of Scientific Advisory Board & Independent Director2.2yrsUS$70.00k0%
$ 0
James Carmichael
Observerno datano datano data
3.1yrs
Average Tenure
62yo
Average Age

Experienced Board: AKTS's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/19 02:53
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aktis Oncology, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Robert BurnsH.C. Wainwright & Co.
Jessica FyeJ.P. Morgan